STAT+: Pharmalittle: GSK to pay up to $3.3 billion for Affinivax; Senate bill tries to avoid another Aduhelm controversy
Good morning, everyone, and welcome to another working week. We hope the weekend respite, which was longer on this side of the pond, was refreshing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has predictably returned. But what can you do? The world, such as it is, keeps spinning. So time to give it a nudge with a cup or more of stimulation, yes? Our choice today is the ever-smooth butter pecan. Feel free to join us. Meanwhile, we have assembled a few tidbits for you to peruse as you settle in. Hope your day is productive and meaningful. And of course, do keep in touch. …
Looking to bolster its vaccines business with new technology, GSK is buying Affinivax in a transaction worth up to $3.3 billion, The Financial Times tells us. The drugmaker expects to pay $2.1 billion up front and “milestone” payments of up to $1.2 billion, if a new Affinivax vaccine for bacterial pneumococcal infections succeeds in trials. Affinivax developed a multiple-antigen presenting system, which creates vaccines that teach the immune system to recognize a number of pathogens at the same time and create protective antibodies and T cells. The company has used the technology in the development of a vaccine to prevent pneumococcal infections, such as pneumonia and meningitis.
Continue to STAT+ to read the full story…
